AIM ImmunoTech Inc. announced the granting of Patent No. 2,032,813 by the Netherlands Patent Office for Ampligen® (rintatolimod), which covers its use in treating post-COVID fatigue. AIM's CEO, Thomas ...
AIM ImmunoTech Inc. announced a reverse stock split of 1-for-100, effective June 12, 2025, aimed at increasing the share price to comply with NYSE American listing requirements. This decision follows ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results